Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal
inserts for the treatment of women who have cervical high grade intraepithelial neoplasia
(CIN2/3).
Participants who receive placebo in this study have the option to receive active drug
(artesunate) after their week 15 colposcopy visit.
Phase:
Phase 2
Details
Lead Sponsor:
Frantz Viral Therapeutics, LLC Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Amarex Clinical Research Frantz Viral Therapeutics LLC Harris Health System (L.B.J. Hospital) M.D. Anderson Cancer Center The Cleveland Clinic